| 标题 |
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet 作者:Zheng Wang; Jia Fan; Shaolai Zhou; Yunfan Sun; Fei Liang; et al 出版日期:2025 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |